<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785354</url>
  </required_header>
  <id_info>
    <org_study_id>1160.263</org_study_id>
    <nct_id>NCT02785354</nct_id>
  </id_info>
  <brief_title>Anticoagulants Comparative Benefit-risk Ratio in Real Life</brief_title>
  <official_title>Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The study is an analysis using the French national health insurance database, six months
      after the beginning of NOAC launch in the NVAF indication.

      The aim is to compare the one-year, two-year and three-year benefit-risk (major bleeding,
      arterial thrombotic events, myocardial infarction (MI), death) between patients starting a
      NOAC and patients starting a VKA for NVAF in 2013
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">April 5, 2016</completion_date>
  <primary_completion_date type="Actual">March 4, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Relevant Bleeding</measure>
    <time_frame>One year</time_frame>
    <description>First hospitalization with primary diagnosis (Tenth Revision codes of the International Classification of Diseases (ICD-10 codes)) of:
Hemorrhagic stroke,
Other critical organ or site bleeding,
Other bleeding (gastro-intestinal bleeding, urogenital bleeding and other bleeding subtype).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Hemorrhagic stroke,
Other critical organ or site bleeding,
Other bleeding with transfusion, or acute post-hemorrhagic anemia or death during hospital stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Thrombotic Event</measure>
    <time_frame>1 year</time_frame>
    <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Ischemic or undefined stroke,
Systemic arterial embolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Coronary Syndrome</measure>
    <time_frame>One year</time_frame>
    <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Myocardial infarction (ST-segment elevation Myocardial infarction (STEMI) and non-ST-segment elevation Myocardial infarction(NSTEMI)),
Unstable angina.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death (All-cause)</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause death (cause of death not available in the database).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite Criterion (Clinically Relevant Bleeding, Arterial Thrombotic Events, Acute Coronary Syndrome, Death)</measure>
    <time_frame>One year</time_frame>
    <description>First event among clinically relevant bleeding, arterial thrombotic event, acute coronary syndrome, or death defined above.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">103101</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>NOAC</arm_group_label>
    <description>New oral anticoagulant groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VKA</arm_group_label>
    <description>VKA group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        New users of NOAC or VKA for NVAF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with NVAF with a first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA in
        2013, with no other identified indication for anticoagulation; Without any VKA or NOAC
        (Pradaxa®, Xarelto®, or Eliquis®) reimbursed dispensation for the last 3 years before the
        first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA

        Exclusion criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.263.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Multiple Locations</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>March 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study ENGEL 2 is a real-world historical cohort study in the French nationwide healthcare claims and hospitalization database (SNIIRAM) including new users of DOAC or VKA for nonvalvular atrial fibrillation (NVAF) in 2013 with a follow-up for one year (main objective).</recruitment_details>
      <pre_assignment_details>The main objective was to compare the risk &amp; effectiveness for dabigatran vs VKA, &amp; for rivaroxaban vs VKA. The main analysis was done for hdPS matched patients (pts.) with atrial fibrillation (AF) diagnosis information in the database.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran</title>
          <description>Patients with a first dispensing of dabigatran in 2013 for NVAF.</description>
        </group>
        <group group_id="P2">
          <title>Rivaroxaban</title>
          <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF.</description>
        </group>
        <group group_id="P3">
          <title>Vitamin K Antagonists</title>
          <description>Patients with a first dispensing of VKA in 2013 for NVAF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27060"/>
                <participants group_id="P2" count="31388"/>
                <participants group_id="P3" count="44653"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27060"/>
                <participants group_id="P2" count="31388"/>
                <participants group_id="P3" count="44653"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The main analysis was on matched patients 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and hdPS (± 0.05).Baseline measures were presented for overall treatment groups and matched populations: dabigatran vs VKA and rivaroxaban vs VKA.</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran</title>
          <description>Patients with a first dispensing of dabigatran in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
        </group>
        <group group_id="B2">
          <title>Rivaroxaban</title>
          <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
        </group>
        <group group_id="B3">
          <title>Vitamin K Antagonists</title>
          <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27060"/>
            <count group_id="B2" value="31388"/>
            <count group_id="B3" value="44653"/>
            <count group_id="B4" value="103101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>The main analysis was on matched patients 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and hdPS (± 0.05).Baseline measures were presented for overall treatment groups and matched populations: dabigatran vs VKA and rivaroxaban vs VKA.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27060"/>
                    <count group_id="B2" value="31388"/>
                    <count group_id="B3" value="44653"/>
                    <count group_id="B4" value="103101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="11.8"/>
                    <measurement group_id="B2" value="73.2" spread="11.8"/>
                    <measurement group_id="B3" value="77.9" spread="11.1"/>
                    <measurement group_id="B4" value="75.2" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dabigatran vs VKA (matched pop)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20489"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="20489"/>
                    <count group_id="B4" value="40978"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" spread="10.7"/>
                    <measurement group_id="B3" value="75.4" spread="10.7"/>
                    <measurement group_id="B4" value="75.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rivaroxaban vs VKA (matched pop)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="23053"/>
                    <count group_id="B3" value="23053"/>
                    <count group_id="B4" value="46106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="75.3" spread="10.7"/>
                    <measurement group_id="B3" value="75.4" spread="10.7"/>
                    <measurement group_id="B4" value="75.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <population>The main analysis was on matched patients 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and hdPS (± 0.05).Baseline measures were presented for overall treatment groups and matched populations: dabigatran vs VKA and rivaroxaban vs VKA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27060"/>
                    <count group_id="B2" value="31388"/>
                    <count group_id="B3" value="44653"/>
                    <count group_id="B4" value="103101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15253"/>
                    <measurement group_id="B2" value="17653"/>
                    <measurement group_id="B3" value="22868"/>
                    <measurement group_id="B4" value="55774"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11807"/>
                    <measurement group_id="B2" value="13735"/>
                    <measurement group_id="B3" value="21785"/>
                    <measurement group_id="B4" value="47327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dabigatran vs VKA (matched pop)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20489"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="20489"/>
                    <count group_id="B4" value="40978"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11164"/>
                    <measurement group_id="B3" value="11164"/>
                    <measurement group_id="B4" value="22328"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9325"/>
                    <measurement group_id="B3" value="9325"/>
                    <measurement group_id="B4" value="18650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rivaroxaban vs VKA (matched pop)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="23053"/>
                    <count group_id="B3" value="23053"/>
                    <count group_id="B4" value="46106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="12557"/>
                    <measurement group_id="B3" value="12557"/>
                    <measurement group_id="B4" value="25114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="10496"/>
                    <measurement group_id="B3" value="10496"/>
                    <measurement group_id="B4" value="20992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinically Relevant Bleeding</title>
        <description>First hospitalization with primary diagnosis (Tenth Revision codes of the International Classification of Diseases (ICD-10 codes)) of:
Hemorrhagic stroke,
Other critical organ or site bleeding,
Other bleeding (gastro-intestinal bleeding, urogenital bleeding and other bleeding subtype).</description>
        <time_frame>One year</time_frame>
        <population>Patients (pts) with a first dispensing (dispen.) of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks (wks.)), gender, age at index date (± 1 year (yr)) and high-dimensional propensity score (hdPS, ± 0.05).</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of dabigatran in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O2">
            <title>VKA (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O4">
            <title>VKA (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Bleeding</title>
          <description>First hospitalization with primary diagnosis (Tenth Revision codes of the International Classification of Diseases (ICD-10 codes)) of:
Hemorrhagic stroke,
Other critical organ or site bleeding,
Other bleeding (gastro-intestinal bleeding, urogenital bleeding and other bleeding subtype).</description>
          <population>Patients (pts) with a first dispensing (dispen.) of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks (wks.)), gender, age at index date (± 1 year (yr)) and high-dimensional propensity score (hdPS, ± 0.05).</population>
          <units>participants with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20489"/>
                <count group_id="O2" value="20489"/>
                <count group_id="O3" value="23053"/>
                <count group_id="O4" value="23053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367" lower_limit="2.2" upper_limit="2.7"/>
                    <measurement group_id="O2" value="668" lower_limit="4.1" upper_limit="4.8"/>
                    <measurement group_id="O3" value="635" lower_limit="3.5" upper_limit="4.1"/>
                    <measurement group_id="O4" value="767" lower_limit="4.2" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during dabigatran or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for dabigatran versus VKA, with hazard ratio (HR) and 95% Confidence Interval (CI ) (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during rivaroxaban or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for rivaroxaban versus VKA, with HR and 95%CI (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Bleeding</title>
        <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Hemorrhagic stroke,
Other critical organ or site bleeding,
Other bleeding with transfusion, or acute post-hemorrhagic anemia or death during hospital stay.</description>
        <time_frame>1 year</time_frame>
        <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of dabigatran in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O2">
            <title>VKA (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O4">
            <title>VKA (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Hemorrhagic stroke,
Other critical organ or site bleeding,
Other bleeding with transfusion, or acute post-hemorrhagic anemia or death during hospital stay.</description>
          <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
          <units>participants with events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20489"/>
                <count group_id="O2" value="20489"/>
                <count group_id="O3" value="23053"/>
                <count group_id="O4" value="23053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" lower_limit="1.0" upper_limit="1.4"/>
                    <measurement group_id="O2" value="341" lower_limit="2.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="280" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O4" value="417" lower_limit="2.2" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during dabigatran or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for dabigatran versus VKA, with hazard ratio (HR) and 95%CI (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during rivaroxaban or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for rivaroxaban versus VKA, with HR and 95%CI (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arterial Thrombotic Event</title>
        <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Ischemic or undefined stroke,
Systemic arterial embolism.</description>
        <time_frame>1 year</time_frame>
        <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of dabigatran in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O2">
            <title>VKA (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O4">
            <title>VKA (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Thrombotic Event</title>
          <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Ischemic or undefined stroke,
Systemic arterial embolism.</description>
          <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
          <units>participants with events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20489"/>
                <count group_id="O2" value="20489"/>
                <count group_id="O3" value="23053"/>
                <count group_id="O4" value="23053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O2" value="321" lower_limit="1.9" upper_limit="2.4"/>
                    <measurement group_id="O3" value="343" lower_limit="1.8" upper_limit="2.2"/>
                    <measurement group_id="O4" value="351" lower_limit="1.9" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during dabigatran or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for dabigatran versus VKA, with hazard ratio (HR) and 95%CI (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during rivaroxaban or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for rivaroxaban versus VKA, with HR and 95%CI (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8341</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acute Coronary Syndrome</title>
        <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Myocardial infarction (ST-segment elevation Myocardial infarction (STEMI) and non-ST-segment elevation Myocardial infarction(NSTEMI)),
Unstable angina.</description>
        <time_frame>One year</time_frame>
        <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of dabigatran in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O2">
            <title>VKA (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O4">
            <title>VKA (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Coronary Syndrome</title>
          <description>First hospitalization with primary diagnosis (ICD-10 codes) of:
Myocardial infarction (ST-segment elevation Myocardial infarction (STEMI) and non-ST-segment elevation Myocardial infarction(NSTEMI)),
Unstable angina.</description>
          <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
          <units>participants with events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20489"/>
                <count group_id="O2" value="20489"/>
                <count group_id="O3" value="23053"/>
                <count group_id="O4" value="23053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" lower_limit="1.1" upper_limit="1.4"/>
                    <measurement group_id="O2" value="238" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O3" value="230" lower_limit="1.2" upper_limit="1.5"/>
                    <measurement group_id="O4" value="277" lower_limit="1.4" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during dabigatran or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for dabigatran versus VKA, with hazard ratio (HR) and 95%CI (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0147</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during rivaroxaban or VKA exposure period (on treatment) using: 1) Cumulative function to estimate the incidence (with death as a competing risk), 2) Fine and Gray model to compare the 1-year risk for rivaroxaban versus VKA, with HR and 95%CI (and death as a competing risk).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0501</p_value>
            <method>Fine and Gray model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death (All-cause)</title>
        <description>All-cause death (cause of death not available in the database).</description>
        <time_frame>1 year</time_frame>
        <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of dabigatran in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O2">
            <title>VKA (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O4">
            <title>VKA (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Death (All-cause)</title>
          <description>All-cause death (cause of death not available in the database).</description>
          <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
          <units>participants with events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20489"/>
                <count group_id="O2" value="20489"/>
                <count group_id="O3" value="23053"/>
                <count group_id="O4" value="23053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="686" lower_limit="4.6" upper_limit="5.3"/>
                    <measurement group_id="O2" value="983" lower_limit="6.4" upper_limit="7.3"/>
                    <measurement group_id="O3" value="908" lower_limit="5.2" upper_limit="6.0"/>
                    <measurement group_id="O4" value="1186" lower_limit="6.9" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during dabigatran or VKA exposure period (on treatment) using: 1) Kaplan-Meier to estimate the cumulative incidence, 2) Cox proportional hazard risk model to compare the 1-year risk for dabigatran versus VKA, with HR and 95%CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox proportional hazard risk model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during rivaroxaban or VKA exposure period (on treatment) using: 1) Kaplan-Meier to estimate the cumulative incidence, 2) Cox proportional hazard risk model to compare the 1-year risk for rivaroxaban versus VKA, with HR and 95%CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox proportional hazard risk model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite Criterion (Clinically Relevant Bleeding, Arterial Thrombotic Events, Acute Coronary Syndrome, Death)</title>
        <description>First event among clinically relevant bleeding, arterial thrombotic event, acute coronary syndrome, or death defined above.</description>
        <time_frame>One year</time_frame>
        <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of dabigatran in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O2">
            <title>VKA (Dabigatran vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
          <group group_id="O4">
            <title>VKA (Rivaroxaban vs VKA)</title>
            <description>Patients with a first dispensing of VKA in 2013 for NVAF, matched 1:1 on the date of the first dispensing, gender, age at index date, and hdPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Criterion (Clinically Relevant Bleeding, Arterial Thrombotic Events, Acute Coronary Syndrome, Death)</title>
          <description>First event among clinically relevant bleeding, arterial thrombotic event, acute coronary syndrome, or death defined above.</description>
          <population>Patients with a first dispensing of DOAC or VKA in 2013 for NVAF. For each comparison (dabigatran versus VKA and rivaroxaban versus VKA), patients were matched 1:1 on the date of the first drug (DOAC or VKA) dispensing (± 2 weeks), gender, age at index date (± 1 year) and high-dimensional propensity score (hdPS, ± 0.05).</population>
          <units>participants with events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20489"/>
                <count group_id="O2" value="20489"/>
                <count group_id="O3" value="23053"/>
                <count group_id="O4" value="23053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1340" lower_limit="8.8" upper_limit="9.8"/>
                    <measurement group_id="O2" value="1970" lower_limit="12.5" upper_limit="13.7"/>
                    <measurement group_id="O3" value="1967" lower_limit="11.1" upper_limit="12.1"/>
                    <measurement group_id="O4" value="2328" lower_limit="13.2" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during dabigatran or VKA exposure period (on treatment) using: 1) Kaplan-Meier to estimate the cumulative incidence, 2) Cox proportional hazard risk model to compare the 1-year risk for dabigatran versus VKA, with HR and 95%CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox proportional hazard risk model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Outcome was analyzed during rivaroxaban or VKA exposure period (on treatment) using: 1) Kaplan-Meier to estimate the cumulative incidence, 2) Cox proportional hazard risk model to compare the 1-year risk for rivaroxaban versus VKA, with HR and 95%CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox proportional hazard risk model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Claims and hospitalization database without any adverse event declaration, and using secondary individual anonymous information. Thus all outcomes studied were reported in aggregate in the final study report.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran</title>
          <description>Patients with a first dispensing of dabigatran in 2013 for NVAF.</description>
        </group>
        <group group_id="E2">
          <title>Rivaroxaban</title>
          <description>Patients with a first dispensing of rivaroxaban in 2013 for NVAF.</description>
        </group>
        <group group_id="E3">
          <title>Vitamin K Antagonists</title>
          <description>Patients with a first dispensing of VKA in 2013 for NVAF.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>DOAC &amp; VKA were prescribed by physicians in their daily practice,with differences for pts &amp; disease characteristics,including stroke &amp; bleeding risk factors.To control this pts were 1:1 matched on date of 1st dispensing, gender,age &amp; hdPS.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

